Tetsuwan Scientific

# High-Level Overview

Tetsuwan Scientific is an AI-driven robotics company that develops autonomous AI scientists—fully autonomous systems combining advanced artificial intelligence with laboratory robots to conduct scientific experiments independently[1]. Founded in 2023, the company addresses a fundamental bottleneck in scientific research: the limited speed, throughput, and scalability of human scientific labor[2]. Rather than automating individual tasks, Tetsuwan focuses on building intelligent agents capable of reasoning, reacting to experimental data, and making autonomous decisions to advance discovery[2].

The company's core offering targets life sciences research, where it helps measure effectiveness, determine dosage, and accelerate the pace of experimentation. By automating routine lab work—such as pipetting and liquid handling—Tetsuwan aims to free human scientists to focus on creative and intellectual synthesis while simultaneously scaling scientific productivity[1][2].

# Origin Story

Founders and Background

Tetsuwan Scientific was founded in 2023 by Cristian Ponce (CEO) and Théo Schäfer (CTO), who met through Entrepreneur First's U.S. program[1]. Ponce holds a background in biological engineering from Caltech and contributed to research in full-genome engineering[1]. Schäfer completed his master's degree in Mechanical Engineering from ETH Zurich, with thesis work conducted at MIT[1]. The duo bonded over shared frustrations about the manual drudgery of lab work—particularly the tedious hours spent pipetting liquids between tubes in genetic engineering[3].

The Pivotal Moment

The company's breakthrough came in May 2024 when the co-founders witnessed OpenAI's multimodal product launch. They recognized a critical insight: large language models had already developed strong scientific reasoning capabilities but lacked physical agency to execute their own suggestions[3]. This "light bulb moment" crystallized their vision—combining LLM reasoning with robotic manipulation to create truly autonomous scientific agents[3].

The team rapidly expanded to seven members, drawing expertise from prestigious institutions including Caltech, ETH Zurich, MIT, and UC Davis[1]. The company is advised by Aaron Kimball, former CTO of Zymergen and Director of Engineering at Benchling[1].

# Core Differentiators

• Intelligence-First Approach: Unlike competitors focused on adding dexterity to robots or optimizing workflow efficiency, Tetsuwan prioritizes adding intelligence to lab automation[2]. Their systems can adapt, reason, and manage themselves autonomously rather than requiring consistent human oversight[2].

• Autonomous Decision-Making: Tetsuwan's robots evaluate experimental results and make modifications independently, building software and sensors to understand calibration, liquid class characterization, and other laboratory properties[3].

• Modular Architecture: The company modifies lower-cost white-label lab robots rather than building proprietary hardware from scratch, reducing capital requirements and accelerating deployment[3].

• Bridging the AI-Robotics Gap: Tetsuwan automates the interface between scientists, lab automation tools, and AI models—closing what the company describes as a "large and expensive gap" that prevents both humans and AI from effectively leveraging existing lab infrastructure[6].

# Role in the Broader Tech Landscape

Tetsuwan is riding the convergence of three powerful trends: the maturation of large language models with scientific reasoning capabilities, advances in robotic manipulation, and the growing recognition that scientific discovery itself is a labor bottleneck constraining innovation[1][3].

The timing is particularly significant. Academic breakthroughs in 2023—including CMU's Coscientist and EPFL's ChemCrow—demonstrated that AI-driven language models could partner with robots to conduct experiments[1]. Tetsuwan is among the first companies to commercialize this research, positioning itself at the intersection of generative AI and life sciences automation[1].

The company's vision aligns with a broader shift in how industries approach automation: moving from task-level efficiency gains to system-level intelligence. In this context, Tetsuwan represents a new category—not just lab automation, but autonomous scientific agents that can reason about experimental design and adapt to results in real time[2].

# Quick Take & Future Outlook

Tetsuwan has demonstrated early traction with its first alpha customer, La Jolla Labs, a biotech company developing RNA therapeutic drugs[3]. The company raised $2.7 million in an oversubscribed pre-seed round led by 2048 Ventures, with participation from Carbon Silicon Ventures, Everywhere Ventures, and influential biotech angels[3].

Looking ahead, the company's success will depend on three factors: (1) expanding beyond its initial alpha customer to demonstrate repeatability across different research domains, (2) improving the robustness of autonomous decision-making in unpredictable lab environments, and (3) navigating the regulatory and safety considerations of deploying autonomous systems in research settings.

If Tetsuwan executes effectively, it could fundamentally reshape how scientific research is conducted—transforming labs from human-centric workspaces into hybrid environments where AI scientists handle routine experimentation while human researchers focus on hypothesis generation and creative synthesis. This shift would represent one of the most consequential applications of AI to date, directly accelerating the pace of scientific discovery itself[1].